Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Most relevant
    COX   FR0013018124

NICOX SA.

(COX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about NICOX SA.
01/06NICOX : Half-year liquidity contract statement for NICOX
AQ
01/05Nicox Secures European Patent For Allergic Conjunctivitis Treatment
MT
01/05Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030
AQ
2021Nicox Screens First Patient in China in Late-Stage Trial For Glaucoma Treatment
MT
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
AQ
2021Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 T..
CI
2021GLOBAL MARKETS LIVE : General Motors, JP Morgan, Pfizer, Novavax, Ford...
2021Nicox Appoints Novartis Executive as Chief Scientific Officer
MT
2021Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-c..
AQ
2021Nicox Appoints Doug Hubatsch as New Chief Scientific Officer to Lead Clinical and Non-C..
CI
2021Nicox Raises $17 Million in Share Placement, Restructures Kreos Bond Financing Deal
MT
2021Nicox Restructures Kreos Capital Bond Financing Agreement and Raises Ç15 Million in Pri..
AQ
2021Number of voting rrights as of November 30, 2021
AQ
2021Nicox Reports Positive Results For Dry Eye Treatment Trial
MT
2021Nicox's Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path..
AQ
2021Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical T..
CI
2021Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
AQ
2021Nicox's NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the A..
AQ
2021Nicox?s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the A..
CI
2021Number of voting rightts as of October 31
AQ
2021NICOX : Provides Third Quarter 2021 Business and Financial Highlights
AQ
2021NICOX : to present at the OIS Glaucoma Virtual Innovation Showcase
AQ
2021NICOX : Launches New Corporate & Investor Website
AQ
2021NICOX : Eye Drug Shows Retinal Cell Protection In Nonclinical Trial
MT
2021NICOX : NCX 470 Shows Retinal Cell Protection in a Nonclinical Model
AQ
2021Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induce..
CI
2021GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
2021NICOX : First Half 2021 Financial Results and Business Update
AQ
2021Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021Nicox S.A. Announces Retirement of José Boyer as Interim Head of R&D
CI
2021GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
2021NICOX : Eye Drug Trial Fails To Meet Efficacy Endpoints
MT
2021NICOX : Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial
AQ
2021Nicox S.A. Announces Results from the NCX 4251 Phase 2B Mississippi Blepharitis Trial
CI
2021GLOBAL MARKETS LIVE : Intel, Moderna, Burberry, Pfizer, SoftwareOne, Swisscom...
2021NICOX : Provides Second Quarter 2021 Business and Financial Highlights and Strategic Updat..
GL
2021NICOX : Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinic..
AQ
2021Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to Its Glaucoma Clini..
CI
2021NICOX : Half-year liquidity contract statement with Kepler Cheuvreux
GL
2021GLOBAL MARKETS LIVE : WM Morrison, IBM, Didi...
2021NICOX : to Get $2 Million from Ocumension Under Amended Zerviate License Deal
MT
2021NICOX : to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment un..
AQ
2021Nicox SA Amends its March 2019 License Agreement with Ocumension Therapeutics
CI
2021NICOX : Completes Treatment Phase of Mid-Stage Trial for Eye Drug
MT
2021NICOX : Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial
GL
2021Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2B Blepharitis Trial
CI
2021NICOX S.A.(ENXTPA : COX) dropped from Next Biotech Index
CI
2021GLOBAL MARKETS LIVE : Amazon, The Gap, Fod, Lockheed Martin, CureVac...
2021Nicox's NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Pha..
GL
2021Nicox SA Presented Results from the Dolomites Phase 2 Clinical Trial Showing That NCX 4..
CI
2021NICOX : Licensee Bausch + Lomb Secures Regulatory Approval for Vyzulta in UAE
MT
2021GLOBAL MARKETS LIVE : Facebook, Toshiba, Fedex, Nike, Microsoft...
2021NICOX : Licensee Bausch + Lomb Receives Approval for VYZULTA« (latanoprostene bunod ophtha..
AQ
2021Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA« (latanoprostene bunod oph..
CI
2021GLOBAL MARKETS LIVE : Siemens, BHP Group, Visa, JP Morgan Chase, Proximus...
2021NICOX : NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the Worl..
GL
2021Nicox SA to Present NCX 470 Dolomites Phase 2 Results in Glaucoma Patients at the Worl..
CI
2021NICOX : Completes Patient Enrollment In Mid-Stage Study Of Eye Drug
MT
2021NICOX : Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Tria..
GL
2021Nicox's Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis T..
CI
2021GLOBAL MARKETS LIVE : Lyft, Activision, General Electric...
2021NICOX : partners with Laboratorios Grin to bring ZERVIATE to Mexico
GL
2021Nicox Partners with Laboratorios Grin to Bring Zerviate to Mexico
CI
2021Nicox's Eye Drug Vyzulta Gets Qatar Nod, Launched in Taiwan
MT
2021NICOX : Licensee Bausch + Lomb Launches VYZULTA« (latanoprostene bunod ophthalmic solution..
PU
2021NICOX : Licensee Bausch + Lomb Launches VYZULTA« (latanoprostene bunod ophthalmic solution..
GL
2021Nicox’s Licensee Bausch + Lomb Launches VYZULTA« (Latanoprostene Bunod Ophthalmic Solut..
CI
2021Nicox Updates on Fera Pharmaceuticals
CI
2021NICOX : Gets Notice of Allowance in US Patent Application for Eye Drug
MT
2021U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Norma..
CI
2021GLOBAL MARKETS LIVE : Honeywell, American Express, Intel...
2021NICOX : NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment
GL
2021Nicox’s NCX 4251 Mississippi Phase 2B Blepharitis Trial Reaches 50% Enrollment
CI
2021U.S. Patents for Nicox's Latanoprostene Bunod, Commercialized as VYZULTA«, Eligible for..
GL
2021U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA«, Eligible for..
CI
1  2  3  4  5  6  7Next
Upcoming event on NICOX SA.